Assessment of changes in expression and presentation of NKG2D under influence of MICA serum factor in different stages of breast cancer
Breast cancer is the most common cancer in women worldwide. In this study, we correlated the serum level of major histocompatibility complex class I-related chain A (sMICA) with expression and presentation of NKG2D receptors on NK cells among patients with breast cancer. Peripheral blood (PB) samples were collected from 49 healthy and 49 breast cancer patients before surgery and chemotherapy. The expression and presentation of NKG2D were assessed using qRT-PCR and flow cytometry, respectively. Furthermore, sMICA levels were determined using ELISA. In flow cytometry, whole blood samples were stained with anti-CD56/NKG2D/CD3 and the obtained results were analyzed using WinMDI software. In addition, SPSS software was used for statistical analysis of data. Significantly higher levels sMICA were detected in the sera of the majority of cancer patients in contrast to healthy volunteers (P < 0.001). The expression and presentation of NKG2D receptor were significantly lower than those in healthy persons, and with an inverse correlation to sMICA and positively correlated with tumor stage. Our study showed that sMICA may have an important role in diminishing the expression and presentation of NKG2D receptor in breast cancer patients and proposes the notion that sMICA can be a target candidate for treatment of breast cancer.
KeywordsBreast cancer NKG2D sMICA Flow cytometry qRT-PCR
Major histocompatibility complex class I chain-related protein
Quantitative real-time PCR
Killer immunoglobulin-like receptors
Enzyme-linked immunosorbent assay
This study is part of the MSc thesis of Reyhaneh Roshani. Specific thanks to Vice Chancellor of Research, Ahvaz Jundishapur University of Medical Sciences, for the financial support, and the authors are grateful to breast cancer patients and normal volunteers for helping in this project.
- 4.Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM, et al. Cancer incidence and mortality worldwide, IARC CancerBase No. 10. Lyon: IARC; 2010.Google Scholar
- 5.Goya M. Iranian annual cancer registration report 2005/2006. Tehran: Ministry of Health and Medical Education, Health Deputy, Center for Disease Control and Prevention; 2007. In Persian.Google Scholar
- 8.Arreygue-Garcia NA, Daneri-Navarro A, del Toro-Arreola A, Cid-Arregui A, Gonzalez-Ramella O, Jave-Suarez LF, et al. Augmented serum level of major histocompatibility complex class I-related chain A (MICA) protein and reduced NKG2D expression on NK and T cells in patients with cervical cancer and precursor lesions. BMC Cancer. 2008;8:16.CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Gregory B, Whitney G. Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res. 2014;21(4):1–6.Google Scholar
- 27.Paul S, Ming-Ru W, Marie-Louise S, Charles S. NKG2D ligands as therapeutic targets. Cancer Immun. 2013;13(8):1–14.Google Scholar
- 30.Karagoz B, Bilgi O, Kandemir EG, Sayan O, Erikci AA, Yilmaz B, et al. Decreased NKG2D expression on natural killer cells in gastric cancer patients. Inter J Hematol Oncol. 2009;19(1):0427.Google Scholar
- 33.Fabbri A, Carcangiu ML, Carbone A. Histological classification of breast cancer. Berlin: Springer; 2008. p. 2–4.Google Scholar